80 related articles for article (PubMed ID: 24954776)
1. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
Budinetz TH; Mann JS; Griffin DW; Benadiva CA; Nulsen JC; Engmann LL
Fertil Steril; 2014 Sep; 102(3):753-8. PubMed ID: 24954776
[TBL] [Abstract][Full Text] [Related]
2. Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study.
Wang Q; Wan Q; Li T; Wang X; Hu Y; Zhong Z; Pu K; Ding Y; Tang X
Arch Gynecol Obstet; 2024 Feb; 309(2):679-688. PubMed ID: 38032411
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Coasting Does Not Affect Oocyte Maturation.
Galal AF; Abbassy HA; AbdElrahman AH; Abdelhafez MS; Badawy A
Gynecol Obstet Invest; 2018; 83(2):145-150. PubMed ID: 28601880
[TBL] [Abstract][Full Text] [Related]
4. GnRH agonist trigger in poor prognosis patients undergoing a multicycle approach through DuoStim or consecutive stimulations: a SWOT analysis.
Vaiarelli A; Ruffa A; Cerrillo M; García-Velasco JA
Curr Opin Obstet Gynecol; 2024 Jun; 36(3):124-133. PubMed ID: 38597577
[TBL] [Abstract][Full Text] [Related]
5. Exploring self-detection of the endogenous LH surge using a urine test as a tool to predict a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
Martinez M; Delgado R; Quevedo E; Guerrero J; Moragues H; Ortiz JA; Bernabeu A; Castillo JC; Bernabeu R
JBRA Assist Reprod; 2023 Sep; 27(3):355-359. PubMed ID: 36749808
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of two different trigger strategies - dual (hCG + Leuprolide) versus hCG trigger - in antagonist non-donor IVF: a randomized controlled trial.
Singh N; Kashyap A; Malhotra N; Mahey R; Vatsa R; Patel G
JBRA Assist Reprod; 2023 Sep; 27(3):467-473. PubMed ID: 37698459
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles.
Kitasaka H; Tokoro M; Kojima M; Fukunaga N; Asada Y
Reprod Med Biol; 2021 Jan; 20(1):96-107. PubMed ID: 33488289
[TBL] [Abstract][Full Text] [Related]
8. Is there a preferred time interval between gonadotropin-releasing hormone (GnRH) agonist trigger and oocyte retrieval in GnRH antagonist cycles? A retrospective cohort of planned fertility preservation cycles.
Ranit H; Shmuel H; Ahlad A; Shirley G; Meny H; Tal I; Assaf BM; Chana AL; Yaakov B; Efrat EB; Anat HK
J Assist Reprod Genet; 2024 Mar; ():. PubMed ID: 38492156
[TBL] [Abstract][Full Text] [Related]
9. Low plasma levels of hCG after 10,000-IU hCG injection do not reduce the number or maturation of oocytes recovered in patients undergoing assisted reproduction.
al-Hassan S; Fishel S; Fleming S; Thornton S
J Assist Reprod Genet; 1998 Nov; 15(10):583-6. PubMed ID: 9866065
[TBL] [Abstract][Full Text] [Related]
10. In vitro fertilization outcomes in a mouse model of gender-affirming hormone therapy in transmasculine youth.
Dela Cruz C; Wandoff A; Brunette M; Padmanabhan V; Shikanov A; Moravek MB
F S Sci; 2023 Nov; 4(4):302-310. PubMed ID: 37579932
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy concerns of long-acting GnRHa trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation.
Ingold C; Bedoschi G
ESMO Open; 2023 Oct; 8(5):101825. PubMed ID: 37717387
[No Abstract] [Full Text] [Related]
12. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
13. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
Casper RF
Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
15. Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related.
Shapiro BS; Andersen CY
Fertil Steril; 2015 Apr; 103(4):874-8. PubMed ID: 25707333
[TBL] [Abstract][Full Text] [Related]
16. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches.
Humaidan P; Engmann L; Benadiva C
Fertil Steril; 2015 Apr; 103(4):879-85. PubMed ID: 25681859
[TBL] [Abstract][Full Text] [Related]
17. Introduction: Gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization.
Casper RF
Fertil Steril; 2015 Apr; 103(4):865-6. PubMed ID: 25681856
[TBL] [Abstract][Full Text] [Related]
18. Cryopreserved oocytes: update on clinical applications and success rates.
Paramanantham J; Talmor AJ; Osianlis T; Weston GC
Obstet Gynecol Surv; 2015 Feb; 70(2):97-114. PubMed ID: 25671372
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
[TBL] [Abstract][Full Text] [Related]
20. The Luteal Phase after GnRHa Trigger-Understanding An Enigma.
Leth-Moller K; Hammer Jagd S; Humaidan P
Int J Fertil Steril; 2014 Oct; 8(3):227-34. PubMed ID: 25379149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
